Sapacitabine

DNA Damage Response

Sapacitabine - man in lab

Sapacitabine is a DNA damage response inhibitor (DDRi). It is an oral prodrug of CNDAC (2’-C-cyano-2’-deoxy-1-β-D-arabino-pentofuranosylcytosine). Both sapacitabine and CNDAC have demonstrated potent antitumor activity in preclinical models.

Sapacitabine has been evaluated in both hematologic cancers and solid tumors. More than 1,000 patients have received sapacitabine in phase 1, 2, and 3 studies. A Phase 3, multicenter, randomized trial (SEAMLESS) has been conducted as a frontline treatment in elderly patients 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for or have refused intensive induction chemotherapy. Sapacitabine has been granted orphan drug designation for the treatment of both AML and myelodysplastic syndrome from the European Medicines Agency and the US Food and Drug Administration.

Clinical Trials

Phase 1/2 in Leukemias:

Clinical trials are registered with ClinicalTrials.gov. Learn more about sapacitabine trial(s).

Access Publications Related to Sapacitabine

View Publications

Learn More About Our Pipeline

Explore Now

Paul McBarron

Executive Vice President, Chief Financial Officer & Chief Operating Officer​

Mr. McBarron has served as a director of the Company since March 2006. Mr. McBarron joined Cyclacel in January 2002 and has over 30 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and served on the Scottish Lifesciences Association Board.